ZAI LAB LIMITED Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ZAI LAB LIMITED (ZLAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $3.24 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2022-05-10
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $3.24, a 67.21% decline year-over-year.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $9.88, a 79.70% decline year-over-year.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $48.68.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $40.60, a 93.52% increase from fiscal 2019.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $20.98, a 49.54% increase from fiscal 2018.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $14.03.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | $3.24 10-Q · filed 2022-05-10 | ||||
| 2021-09-30 | $82.21 10-Q · filed 2021-11-09 | ||||
| 2021-06-30 | $81.37 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $9.88 10-Q · filed 2022-05-10 | $162.02 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $40.60 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $34.91 10-Q · filed 2021-11-09 | ||||
| 2020-06-30 | $33.51 10-Q · filed 2021-08-09 | ||||
| 2020-03-31 | $48.68 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | $20.98 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | $18.72 6-K · filed 2020-01-21 | ||||
| 2019-06-30 | $18.56 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $14.03 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $14.26 6-K · filed 2020-01-21 | ||||
| 2017-12-31 | $13.92 20-F · filed 2020-04-29 | ||||
| 2016-12-31 | $6.94 20-F · filed 2019-03-29 | ||||
| 2015-12-31 | $1.62 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |